Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Patients With Dry Eye

Completed · Phase 2 · Has a placebo group

Conditions studied: Dry Eye Syndromes, Keratoconjunctivitis Sicca

In brief

The purpose of this study is to evaluate the safety and efficacy of rebamipide 2% suspension for the treatment of patients with dry-eye.

Key facts

Study ID

NCT01027013

Run by

Kubota Vision Inc.

People needed

220

Starts

2009-12-01

Expected to finish

2010-11-01

Last updated by the study team

2012-01-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years and older
• Diagnosis of dry eye as defined by the protocol

You may not qualify if…

• Ongoing ocular disease that may interfere with study parameters.
• Inability to stop using topical ophthalmic medications throughout the duration of the study
• Inability to stop the use of contact lenses for the duration of the study.

Where it is running

• The Eye Care Group, P.C. — Waterbury, Connecticut, United States
• Richard Eiferman, MD — Louisville, Kentucky, United States
• Central Maine Eye Care — Lewiston, Maine, United States
• Ora, Inc — Andover, Massachusetts, United States
• Total Eye Care, P.A. — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.